Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: A review.
Chika Vera AnekweYoon Ji AhnSimar Singh BajajFatima Cody StanfordPublished in: Annals of the New York Academy of Sciences (2024)
This review aims to summarize pharmacological interventions that may affect adiposity and metabolic equilibrium in individuals with obesity. Pharmacological therapy is frequently used to treat medical conditions that are both directly related to obesity (such as hypertension and type 2 diabetes) and indirectly related to obesity (such as asthma, insomnia, and type 1 diabetes). This pharmacological therapy may result in weight gain and alterations in the metabolic profile. Many medication classes are implicated in the pharmacologic causes of weight gain, including antipsychotics, glucocorticoids, beta-adrenergic blockers, tricyclic antidepressants, antihistamines, insulin, neuropathic agents, sleep agents, and steroids. This article describes the mechanisms of action and pathways of pharmacological interventions causing obesity.
Keyphrases
- weight gain
- type diabetes
- body mass index
- birth weight
- weight loss
- insulin resistance
- physical activity
- metabolic syndrome
- healthcare
- cardiovascular disease
- emergency department
- stem cells
- chronic obstructive pulmonary disease
- major depressive disorder
- adipose tissue
- bipolar disorder
- adverse drug
- electronic health record
- cell therapy
- angiotensin converting enzyme
- molecular dynamics simulations